Objectives. To investigate the prevalence of chronic pain and opioid management among patients with chronic kidney disease (CKD).
Introduction
According to the US Centers for Disease Control and Prevention (CDC) National Health and Nutrition survey in the United States, there are approximately 20 million patients with chronic kidney disease (CKD), of varying levels of severity. A CDC survey showed a different percentage of CKD patients in the United States (Table 1) ; of these CKD patients, 23% were age 60 to 69 years and 49% were older than age 70 years [1] . Thus, millions of CKD patients suffer from chronic pain symptoms related to CKD and its comorbidities and require pain management, including analgesic therapy [2] .
CKD patients who are on dialysis have high comorbid disease burden and markedly reduced quality of life (QoL) compared with the general population [3, 4] and with patients with other chronic diseases [5] . Chronic and acute pain is often a common symptom and a contributor to reduced QoL among patients with CKD [6] . One study reported chronic pain in up to 47% of patients with stage 5 CKD [7] . A Swiss survey of 123 patients on dialysis found that more than half of the patients experienced chronic pain, of which two-thirds reported a pain intensity of greater than 5 on a 0-10 visual analog pain scale [8] . Half of these patients with chronic pain identified musculoskeletal pain as the etiology. The authors concluded that pain among patients with CKD is often underestimated and clearly interferes V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com with sleep and QoL [8] . A survey of 100 patients with CKD receiving dialysis in Italy found that almost all patients reported moderate pain with a rating of 5-6 on a 0-10 numerical pain rating scale [9] . In addition, most patients were only receiving anti-inflammatory analgesics for pain management, and in fact were using these irregularly [9] . A Canadian survey of 591 hemodialysis patients reported that pain was experienced among 72% of patients, of moderate or severe intensity in 46% of all patients [10] . The authors concluded that the symptom burden in CKD was substantial and had a significant negative impact on all aspects of the hemodialysis patients' QoL [10] .
The etiology of the pain may be related to procedural pain related to the management of CKD or pain resulting from common associated diseases, such as diabetes and vascular disease. Musculoskeletal pain (63%) from osteoarthritis was the most common etiology; other causes of pain included peripheral vascular disease, bone disease (renal osteodystrophy, osteoporosis with resulting spinal fractures), inflammatory arthritis, primary renal disease (such as polycystic kidney disease), painful peripheral neuropathy, or procedural pain (needle insertion, osmolar shift cramps with dialysis, dialysate infusion pain) [11, 12] .
A review of chronic pain among patients with stage 5 CKD noted that recent studies have shown a prevalence of 37-50% of hemodialysis patients experience chronic pain and that the majority (82%) rate their pain as moderate to severe in intensity [11] . A Canadian prospective cohort study of 205 dialysis patients found that 50% of patients reported pain as a symptom. Of these patients, 32% were administered no analgesics, 29% received nonopioid analgesics, 26% were prescribed weak opioids (codeine, propoxyphene, pethidine, and oxycodone), and only 10% were provided strong opioids (hydromorphone, methadone, fentanyl, and morphine) [13] . An additional study of 162 dialysis patients reported that 75% of patients experienced inadequate pain management, resulting in impaired QoL [14] . Studies have shown that chronic pain impairs QoL in CKD patients as it interferes with functional activity and is associated with depression, anxiety, and sleep disturbances [15] [16] [17] .
Several factors have been found to account for undertreatment of chronic pain in the CKD population. Two recent studies evaluating pain among patients with stage 5 CKD showed that patients with QoL-limiting chronic pain often chose not to report pain unless specifically asked about it [16] . Another study of hemodialysis patients observed that nephrologists commonly failed to document many symptoms that were reported by their patients, including pain [18] . Davison reported that patients with CKD often fail to seek medical attention until pain becomes severe [19] for several reasons. Some patients believe that pain is chronic and inevitable, and thus tend to "put up with it." Others fear addiction and some discontinue analgesics because of adverse side effects [19] . Indeed there is an increased risk of opioid-related constipation among patients with CKD as these patients are generally on fluid restrictions. Furthermore, patients with CKD are often burdened by multiple prescription drugs and are reluctant to add additional analgesia medications to their tablet burden [20] . Physicians also may limit the use of opioids in the management of chronic pain for patients with stage 5 CKD due to concerns regarding increased risk of adverse effects in these patients with reduced renal clearance [21] . Together these factors contribute to the underreporting and underrecognized and ineffective chronic pain management strategies among patients with CKD.
An older systematic review has documented that the World Health Organization (WHO) guidelines for the stepwise selection of analgesics based on pain severity can be adapted for CKD patients [7] . Another review paper recommended tramadol for moderate pain and methadone and fentanyl use for severe pain in CKD patients [22] . The most recent review reported different patterns of opioid use among chronic pain-suffering dialysis patients who visited different centers [12] . Therefore, based on the available literature, the primary objective of this systematic review is to measure the prevalence of chronic pain and opioid management of chronic pain among CKD patients; it will also describe the reasons for opioid prescription, the effectiveness of symptom control, and associated adverse events.
Methods
This systematic review followed the review process methods of evidence-based systematic reviews and meta-analysis of randomized trials and observational studies [23] [24] [25] [26] [27] [28] [29] [30] , Cochrane guidelines [28, 29, 31] , Standards for Reporting Observational Studies (STROBE) [32] , and quality of reporting of analysis [24] . Research questions were: 1) What is the prevalence of opioid use, types of opioids, dosage, and reason for opioid use in chronic kidney disease patients with chronic pain that are available in the literature? 2) What is the effectiveness of pain control and the risk of associated adverse effects with chronic opioid pain management in chronic kidney disease patients based on available literature? Studies eligible for inclusion included randomized controlled trials (RCTs), prospective nonrandomized, case-control, cohort, and cross-sectional studies in the English language. Case reports, case series, book chapters, reviews, animal studies, studies on children, and non-English language studies were excluded. Participants were adult (>18 years) patients with chronic pain (> 90 days) in all stages of CKD. Types of intervention included opioid (morphine, methadone, hydromorphone, oxycodone, hydrocodone, buprenorphine, and fentanyl) therapies (oral, intrathecal, and transdermal) for a minimum length of at least one week. The main outcome measures were prevalence of opioid use, opioid dose, duration, and reason; along with effectiveness of symptom control and associated adverse events in chronic kidney disease patients (with and without dialysis) treated with opioids for chronic pain management. Key words and combinations of key words were used to search the electronic databases and were organized following the Population Intervention Control Outcome (PICO) model [33] . Different combinations of the topics were made with the use of AND, OR, and NOT in order to achieve a specific selection of literature. The search strategy included the terms such as opioid, morphine, methadone, hydromorphone, oxycodone, hydrocodone, buprenorphine, fentanyl, narcotic, chronic kidney disease, end-stage renal disease (ESRD), hemodialysis, peritoneal dialysis, and dialysis. Together with the databases, the reference lists in the articles were scanned separately for relevant publications. Independent selections in three categories (irrelevant, possibly relevant, and relevant) were made by two researchers after reading the full texts.
Studies were selected in an unblinded standardized manner. Two review authors screened the abstracts of all identified studies against the inclusion criteria. Any disagreements between reviewers were resolved by a third author for consensus. All articles with possible relevance were then retrieved in full text for a comprehensive assessment of internal validity, quality, and adherence to inclusion criteria. Upon review, only the relevant articles were selected for qualitative and quantitative analysis. The studies providing appropriate study design, statistical evaluations, and outcome evaluations were reviewed.
Validity Assessment
The quality of each individual article used in this analysis was assessed by Cochrane Review Criteria for randomized trials [28] and the Newcastle-Ottawa Scale for case-control and cohort studies [34] . Studies achieving Cochrane scores of 9 or higher were considered as high quality, scores of 6 to 8 as moderate quality, and studies scoring less than 6 of low quality [28] . The methodological quality assessment for observational studies was carried out utilizing Newcastle-Ottawa Scales as illustrated in Table 2 (see Supplementary ma terial online). Studies achieving scores of 75% or higher were considered high quality; scores of 50% were considered moderate quality; and studies scoring less than 50% were considered low quality [35] . The evidence was synthesized based on published methods of the American Pain Society [30] . Figure 1 gives an overview of the search strategy and is based on study selection recommended by Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) [26] . One hundred thirty-one studies were identified and assessed for eligibility by review of published abstracts; of these 131 studies, 22 met inclusion criteria and 109 were excluded as reviews/case report/case series publications. Among the included studies, there were no randomized controlled trials and 22 were either case-control, prospective nonrandomized, cohort, or cross-sectional studies. After review of the full text, we excluded 10 additional studies and thus had 12 evaluable studies [13, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] for quantitative and Table 2 Methodological quality assessment for cohort studies utilizing Newcastle-Ottawa quality assessment scale on the 12 eligible studies (Alphabetically arranged studies). A study can be awarded a maximum of one star for each numbered item within the selection and outcome categories. A maximum of two stars can be given for comparability.
Results

Methodological Quality Assessment
HD Studies
Non-HD Studies 3) Adequacy of follow up of cohorts: a) complete follow-upall subjects accounted for * b) subjects lost to followup unlikely to introduce bias -small number lost <30% qualitative analysis (Tables 2 and 3 in the Supplementary Materials online). The subjects were of different ages, different opioid doses, and different classes of opioid medications. Patients frequently had several comorbid conditions (Table 3) .
After evaluating the complete article, a methodological quality assessment for observational studies was carried out utilizing Newcastle-Ottawa Scales. Out of 12 studies, four were of high quality [13, 36, [40] [41] [42] [43] [44] [45] ; six were of moderate quality [38, 39, 42, 43, 44, 46] , and the remaining two were low-quality studies (Table 2 ) [37, 41] .
Study Characteristics
Patient baseline characteristics and eligibility criteria were reported in most of the studies, but few described the proportion of patients with missing data. Each study had a different patient cohort. In one of the studies, analgesic prescription was more likely among the elderly, women, and patients with cardiovascular disease, lung and psychiatric disease, cancer, and recurrent cellulitis [36] .
Nine of the eligible studies described opioid use among dialysis patients [13, [36] [37] [38] [39] [40] [41] [42] [43] . The prevalence of opioid use in the individual studies was quite variable. Davison et al. reported in 205 hemodialysis (HD) patients that 26% were administered weak opioids and 10% were administered strong opioids [13] . In Bailie et al., the authors described two-point prevalence such that in May 1997 among 2,988 patients 18% were on any opioid, 2.7% on opioid þ acetaminophen, 0% on opioid with COX-2 (cyclooxygenase-2), and 1.9% on opioid with nonsteroidal anti-inflammatory drugs (NSAIDs). Their results in September 2000 among 2,476 patients showed 15% were on any opioid, 1.7% on opioid with acetaminophen, 1.2% on opioid with COX-2, and 0.6% on opioid with NSAIDs [36] . In a study of 75 patients on chronic thrice-weekly HD in Allegheny County, Pennsylvania, among 27 patients with bone/joint pain, 13 (48%) were receiving analgesic treatment. Of these 13 patients, six were taking both an opioid and Number of full-text articles assessed for eligibility (22) Number of studies included in qualitative synthesis (12) Number of studies included in quantitative synthesis (Systematic Review) RCT (0); non-RCT (12) Number of additional records identified through other sources (6) Number of records excluded (10) Included Eligibility Screening Identification Figure 1 The flowchart based on study selection recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) search strategy. Possibly relevant (discussed to arrive at a consensus) and relevant (included). After discussion, there was a 100% final consensus between the three researchers. RCT ¼ randomized controlled trial. 
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over-the-counter agent, four were taking an opioid only, and three were using over-the-counter NSAIDs or acetaminophen [37] .
The most commonly prescribed opioids also varied across studies. Davison [40, 42] . Three of the DOPPS studies combined to report greater than 23,000 unique patients, with more than 90% of these patients receiving hemodialysis [36, 40, 42] .
The duration of opioid use reported also varied among studies. In a large DOPPS study, the duration of opioid use averaged more than 12 months for 50% of patients and more than 36 months for another 25% [36] , whereas it was for a minimum of at least one week in the Filitz et al. study [41] .
The specific reasons for opioid use and the effectiveness of symptom control were examined only in a few studies [13, 36] . One opioid study reported pain in 50% of subjects, and patients with pain had been on HD therapy longer (52 months) than those without pain (38 months) [13] . These authors reported that musculoskeletal pain was the most common (65%) etiology, followed by dialysis procedure-related pain (14%), peripheral neuropathy (15%), and peripheral vascular disease (10%) [13] .The effectiveness of pain control with opioids varied across studies examining this outcome. Davison et al. found that 38% of patients on weak (codeine, propoxyphene, pethidine, and oxycodone) or strong (hydromorphone, methadone, fentanyl and morphine) opioids still reported pain of moderate to severe intensity within the last 24 hours of interview [13] , whereas Bailie et al. estimated that around 75% of patients reporting moderate to very severe pain were not prescribed analgesics [36] . It is interesting that Davison et al. considered oxycodone a weak opioid [13] ; however, many studies consider tramadol, dihydrocodeine, and codeine weak opioids and morphine, fentanyl, oxycodone, buprenorphine, hydromorphone, methadone, and tapentadol strong opioids [47] .
Some studies have examined associations between opioid use and at least one potential adverse effect such as falls, poor sleep quality, sexual dysfunction, and hip fractures [37, 39, 40, 42] , but none of the studies used rigorous methodology. The poor sleep quality in CKD patients may be due to several reasons other than chronic pain such as snoring, daytime napping, breathing problems, and pruritus [48] . One study investigated 308 patients on thrice-weekly HD with a median age of 71 years and found that 28% who fell were on an opioid derivative, whereas 9.7% were not on opioids (P < 0.001) [39] . One of the DOPPS studies investigated sleep quality (SQ) in 11,351 HD patients and found that 34% of patients with poor SQ were prescribed opioid medication when compared with 22% of good SQ patients [40] . In Carreon et al., 38% HD men reported difficulty with sexual arousal [37] . The patients prescribed laxatives were almost twice as likely to be on an opioid (odds ratio ¼ [42] .
Several studies examined specific opioids such as buprenorphine and fentanyl for safety among patients with CKD. Buprenorphine is a partial agonist at mu opioid receptors; it is also an antagonist at kappa opioid receptors, an agonist at delta opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors. Its clinical actions result from binding to the opioid receptors. The US Food and Drug Administration has approved transdermal patch for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time [49] . Filitz et al. studied the disposition of transdermal buprenorphine and its metabolite norbuprenorphine in 10 patients with stage 5 CKD [41] . The blood samples obtained showed no increase in levels of buprenorphine and norbuprenorphine at doses up to 70 lg/hour transdermal buprenorphine. Stable analgesic effects as seen by unchanged buprenorphine plasma levels in the presence of HD were also seen in the presence of a transdermal buprenorphine patch [41] . In another study, 42 outpatients with or without renal impairment were treated with transdermal buprenorphine or transdermal fentanyl. The authors reported that transdermal buprenorphine, in outpatients with cancer and renal impairment, was as effective, safe, and tolerable as fentanyl in patients without such impairment [45] . These studies together suggest relative safety for the use of buprenorphine or fentanyl in the presence of renal impairment.
Several studies examined both the effectiveness of different opioids and opioid-related adverse effects. In 14 dialysis patients, methadone plasma concentrations were more stable during HD compared with hydromorphone (HM), although there were no differences between the two opioid groups with respect to pain scores, side effect profile, or QoL. Methadone therapy was not associated with an increased rate of adverse events [43] . However methadone has been associated with several lethal side effects that should be kept in mind by prescribing clinicians [50] . A retrospective study involving 54 patients with stage 3 to stage 5 kidney diseases showed that parenteral hydromorphone has few neuroexcitatory symptoms until hydromorphone-3-glucuronide (H3G) accumulates beyond a neurotoxic threshold. In this same study, side effects occurred with increasing dose or duration, tremor 11 (20%), myoclonus 11 (20%), agitation 26 (48%), and cognitive dysfunction 21 (39%) [46] . A smaller study of 12 hemodialysis patients with chronic pain investigating the effect of immediate-release hydromorphone did not show neurotoxic side effects [38] . The authors reported that hydromorphone can be safely and effectively used in selected HD patients. A retrospective study of 55 palliative care patients suggested that hydromorphone is a flexible second-line alternative to morphine that is particularly useful when intolerable side effects such as cognitive/drowsiness/nausea are experienced [44] .
Among the 10 excluded studies, specific details about reasons for exclusion and conclusions are shown in Table 4 (see the Supplementary Data online) [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] . Unruh et al. reported that three quarters of dialysis patients described impaired sleep and 14% had a decline in sleep quality in the first year of treatment. Poor baseline sleep quality was associated with lower SF-36 physical and mental component summary scores, vitality scores, and bodily pain scores (all P < 0.001) [58] . One excluded study suggested that interventions directed toward treating pain on non-HD days may improve CKD patient survival [54] .
Clinical Relevance
The clinical relevance of the included studies was evaluated according to five questions recommended by the Cochrane Back Review Group [28] . Each question was scored as positive (þ) if the clinical relevance item was met, negative (-) if the item was not met, and unclear (?) if data were not available to answer the question. Clinical relevance of the selected articles was based on patient description, description of interventions and treatment settings, clinically relevant outcomes, clinical importance, and benefits vs potential harms. Of the 12 evaluable studies, four met criteria with a score of 5/5, while others scored 3/5.
Analysis of Evidence
The evidence was synthesized based on the Chou et al. conditions [30] . The available published evidence is fair for a high prevalence of chronic pain among patients with chronic kidney disease and that opioids are not commonly used for the treatment of chronic pain in patients with CKD. Dosage adjustment and high caution with careful symptom monitoring is needed when CKD patients are on codeine, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tramadol. Propoxyphene and meperidine are not recommended for CKD patients. Buprenorphine transdermal (TD) and fentanyl TD with monitoring when patients are on long-term use can be considered for this population.
Discussion
In this systematic review, the prevalence of opioid use in CKD patients was highly variable across studies, and the available published evidence is fair that opioids are infrequently used for the treatment of chronic pain among patients with CKD. The use of opioid medications for the treatment of patients with CKD ranged between 18-36% [13, 36] . Of note, many studies typically differentiated analgesics into categories only of strong and weak opioids, opioids with a combination of NSAIDS or acetaminophen, or NSAID analgesics [13, 36, 37] . Concomitant with the finding of infrequent opioid use was that several studies reported pain to be inadequately managed in this population [13, 36] . The reported use of opioids in CKD patients is lower than expected considering that patients on dialysis report significantly higher pain and worse physical functioning than the general population [61, 62] . One of the limitations of our study is that we focused only on opioid management and have not included nonopioid studies in CKD patients. Additional research is needed into the exact nature of chronic pain among patients with CKD and the role of chronic analgesic therapy.
It is apparent from this review that at present there are no clear guidelines or randomized clinical trials for the appropriate management of chronic pain among patients with CKD. A lack of evidence-based guidelines is likely a major factor contributing to the undertreatment of chronic pain and the inconsistent use of opioids in patients with CKD [13, 36] , an important need given both undertreatment and the potential for increased adverse effects among this population (Table 5 ). In addition to chronic pain, CKD patients also may suffer from fatigue and depression, which may worsen chronic pain symptoms. Furthermore, because there is a high prevalence of specific comorbid conditions among patients with CKD, such as anemia and renal osteodystrophy, specific analgesic guidelines should include attention to these comorbid factors [12] . Additional randomized controlled trials assessing the efficacy and safety of opioids and other medications in patients with CKD are greatly needed.
The World Health Organization recommendations for opioid therapy in acute and cancer pain are published [63] ; some authors debate whether these recommendations can be extrapolated to patients with CKD [16, 64] although following a review of current literature, Murtagh et al. recommended implementation of WHO guidelines in the patient population with CKD [7] . However, based on our review, opioid therapy among patients with CKD should be closely monitored, particularly in elderly patients with comorbid conditions such as diabetes and hypertension [65] . Opioid therapy may exacerbate symptoms attributed to hemodialysis such as orthostatic hypotension and impaired cognition, possibly worsening The majority of respondents described the overall quality of life as "moderate," while the self-efficacy in pain depended on comorbidity or complications that accompany the process of hemodialysis
symptoms of nausea, vomiting, fatigue, and constipation [21, 44] . Physicians may currently be reluctant to prescribe chronic opioids to patients with CKD because of fear of more serious side effects such as central nervous system depression, or physical and psychological dependence [21] . The emergence of more stringent opioid prescribing guidelines and increased physician caution with opioids may further reduce the use of opioid therapy for the treatment of CKD patients [66] . For example, the recent CDC guidelines suggest that clinicians use additional caution and increased monitoring to minimize risks of opioids prescribed for patients with renal insufficiency, given their decreased ability to process and excrete drugs, susceptibility to accumulation of opioids, and reduced therapeutic window between safe dosages and dosages associated with respiratory depression and overdose. They recommend evaluating benefits and harms within one to four weeks of starting opioid therapy for chronic pain or after dose escalation and every three months or more frequently as clinically indicated. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids. Additionally they recommend, when starting opioid therapy for chronic pain, that clinicians should prescribe immediate-release opioids instead of extended-release/ long-acting (ER/LA) opioids and prescribe the lowest effective dosage. Clinicians should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when increasing dosage to !50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to !90 MME/day or carefully justify a decision to titrate dosage to !90 MME/day [67] .
Results of this review suggest that there are few specific recommendations for opioids in the treatment of chronic pain for patients with CKD (Table 5 ) [21, 41, 53, . It is possible, based on knowledge of opioid pharmacodynamics and pharmacokinetics, to suggest caution with certain opioids in the treatment of patients with CKD.
Codeine is metabolized to the active opioid morphine and will therefore accumulate morphine-3-glucuronide and morphine-6-glucuronide metabolites in patients with renal failure [64, 71] . Therefore, morphine products and codeine should likely be used with significant caution in patients with CKD. Similarly, hydromorphone is metabolized to the active metabolites hydromorphone-3-glucuronide and hydromorphone-3-glucoside, which may accumulate in patients with CKD, causing neuro-excitatory side effects [79] . Because hydrocodone is metabolized to hydromorphone, clinicians should be cautioned in the use of both hydromorphone and hydrocodone for patients with CKD.
Oxycodone is extensively metabolized in the liver, but with the parent oxycodone and the metabolites excreted primarily by the kidney. Thus, oxycodone should be used with caution among patients with CKD [75] . Oxymorphone has been shown to have an increased bioavailability of approximately 60% among patients with renal impairment [90] ; therefore oxymorphone should be used cautiously in patients with CKD.
Meperidine [100] and propoxyphene [101] should probably not be used for any long-term opioid therapy in patients with or without CKD. Propoxyphene (dextropropoxyphene) is no longer available in the United States due to iatrogenic events (cardiotoxicity, seizures, etc.) that far outweighed any perceived therapeutic benefit [94] .
Methadone's pharmacokinetics seems to be relatively unaffected in patients with CKD; however, methadone is poorly removed by hemodialysis [83, 84] . As methadone has a long elimination half-life of approximately 36 hours (or longer among the elderly), it should be used cautiously among patients with CKD.
Tramadol is extensively metabolized in the liver; however, the active metabolites are excreted primarily with the kidney [93, 94] . Thus caution should be used for patients with CKD being treated with tramadol, typically using a lower dose decrease and increasing the interval between doses, with careful monitoring. Tapentadol, which has been associated with improvements in pain and QoL for patients with and without a neuropathic component to their chronic pain, may provide clinically meaningful benefits over classic opioid analgesics for the long-term management of severe chronic pain in mild to moderate renal insufficiency [99] . It has a low risk of withdrawal after cessation of therapy, a favorable pharmacokinetic profile (allowing for coadministration with other medications), and low potential for abuse [99] .
Two opioids that seem to be least effected among patients with CKD are transdermal fentanyl and transdermal buprenorphine. Transdermal fentanyl is primarily oxidized in the liver with no active metabolites and may be administered to patients with CKD. However, because fentanyl is not well dialyzed, it should be used with caution [73, 74] . Transdermal buprenorphine is primarily metabolized to norbuprenorphine and N-dealkylbuprenorphine [41, 67] . The parent buprenorphine and two-thirds of the metabolites are excreted via the gut, with only one-third renally excreted [53] . A recent study conducted in 42 outpatients with cancer reported that transdermal buprenorphine was as effective, safe, and tolerable as transdermal fentanyl in patients with or without renal impairment [45] and may be an effective and relatively safe option for patients with CKD [68] .
Conclusions
Based on a systematic review of the current literature, there is fair evidence for the high prevalence of chronic pain among patients with CKD, as well as fair evidence for the inadequate use of opioid therapy for the treatment of CKD patients with chronic pain. Clinicians are in need of additional and well-designed randomized controlled trials that focus on the indications for opioid therapy, appropriate opioid doses and dosing intervals, outcomes with adequacy of symptom control, and reporting on the incidence of adverse side effects.
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